Open Nav

Please submit your session questions in advance at

Daré Bioscience

  • Sabrina Johnson, Daré Bioscience, Inc.

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s sexual health, vaginal health, fertility, and contraception. The company’s mission is to identify, develop and bring to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in the areas of contraception, vaginal health, sexual health, and fertility.

Daré’s product portfolio includes potential first-in-class candidates in clinical development: Ovaprene®, a non-hormonal, monthly contraceptive vaginal ring; and Sildenafil Cream, 3.6%, a potential treatment for female sexual arousal disorder utilizing the active ingredient in Viagra®, as well as a proprietary solution-to-gel formulation of clindamycin to treat bacterial vaginosis via a single application, DARE-BV1.

  • Date:Tuesday, February 12
  • Time:9:45 AM - 10:00 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23463
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Increase investor and BD awareness of upcoming milestones
  • Company
  • Company HQ City:san diego
  • Company HQ State:California
  • Company HQ Country:United States
  • Ticker:DARE
  • Exchange:NASDAQ
  • CEO/Top Company Official:Sabrina Martucci Johnson
  • Year Founded:2015
  • Main Therapeutic Focus:Reproductive/Sexual Health
  • Lead Product in Development:DARE-BV1, Ovaprene, Sildenafil Cream
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):6
Sabrina Johnson
Daré Bioscience, Inc.